Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.

Abstract

SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients.

• Authors: Eugenia Abella, Macedonia Trigueros, Edwards Pradenas, Francisco Muñoz-Lopez, Francesc Garcia-Pallarols, Randa Ben Azaiz Ben Lahsen, Benjamin Trinité, Victor Urrea, Silvia Marfil, Carla Rovirosa, Teresa Puig, Eulàlia Grau, Anna Chamorro, Ruth Toledo, Marta Font, Dolors Palacín, Francesc Lopez-Segui, Jorge Carrillo, Nuria Prat, Lourdes Mateu, Bonaventura Clotet, Julià Blanco, Marta Massanella, VAC-COV-GM-HMAR, KING Cohort Extension and CoronAVI@S studies
• Journal: Life science alliance (Life Sci Alliance) Vol. 5 Issue 12 (08 12 2022) ISSN: 2575-1077 [Electronic] United States
• PMID: 35961779 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 Abella et al.

Chemical References

• COVID-19 Vaccines

Topics

• COVID-19 (prevention & control)
• COVID-19 Vaccines
• Cross-Sectional Studies
• Humans
• Monoclonal Gammopathy of Undetermined Significance (pathology, therapy)
• Paraproteinemias
• SARS-CoV-2
• Vaccination